Elicio Therapeutics (ELTX) announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed ...

Phase 1A safety evaluation of ELI-002 7P in which a cohort of ~13 patients received fixed 10.0 mg doses of AMP-CpG adjuvant at one of two AMP-Peptides 7P doses levels (1.4 mg or 4.9 mg); 1A cohort ...

About ELI-002 Our lead product candidate, ELI-002, is a structurally novel investigational Amphiphile (“AMP”) cancer vaccine that targets cancers that are driven by mutations in the mKRAS-gene ...

The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present in 25% of all solid tumors, thereby increasing the potential ...

The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations (G12D, G12R, G12V, G12A, G12C, G12S and G13D) present in 25% of all solid ...

As part of its randomized phase 2 AMPLIFY-7P study of ELI-002 7P as an adjuvant monotherapy in Kirsten Rat Sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma (PDAC), Elicio Therapeutics Inc. ELTX ...

ELI-002 immunogenicity was based on a longitudinal ex vivo analysis of peripheral T cells collected from a total of 12 evaluable patients who received either a 1.4 mg dose or the recommended Phase ...

ELI-002 2P is currently being studied in a Phase 1 trial (“AMPLIFY-201”) in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy (NCT04853017).

ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary lymph node-targeting AMP technology to treat cancers driven by seven common mutations in KRAS ...

About ELI-002 ELI-002 is a structurally novel investigational AMP therapeutic immunotherapy targeting mutant KRAS-driven cancers. KRAS mutations are among the most prevalent human cancers.